Our technical outlook and strategy for the San Diego-based biotech.
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.
What does it mean when a stock is called very speculative?
Shares of the provider of animal health technology could afford to see more development and sideways price action after their big post-earnings jump.
Let's find a trainer versed in technical analysis as we check out the charts.
Let's check out the charts of this medical technologies company.
I see upside back to above $70 regardless of whether the company gets taken private.
The contract research company's shares will not stay in a tight trading range indefinitely, so would-be buyers should be prepared to act.
Google's Project Nightingale exemplifies the headline risk facing big-cap tech names.
Let's review the charts of HUM.